Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 6 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 3 | 0 | 0 |
| 2M Ago | 2 | 2 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Pacific Biosciences, revealing an average target of $3.64, a high estimate of $8.00, and a low estimate of $2.00. A decline of 57.92% from the prior average price target is evident in the current average.
Diving into Analyst Ratings: An In-Depth Exploration
The analysis of recent analyst actions sheds light...
Login or create a forever free account to read this news
Sign up/Log in